Screening chimeric GAA variants in preclinicalstudy results in hematopoietic stem cell genetherapy candidate vectors for Pompe disease

• Published in: Molecular therapy. Methods & clinical development 2022-12, Vol.27, p.464-487
• Main Authors: Dogan, Yildirim, Barese, Cecilia N., Schindler, Jeffrey W., Yoon, John K., Unnisa, Zeenath, Guda, Swaroopa, Jacobs, Mary E., Oborski, Christine, Maiwald, Tim, Clarke, Diana L., Schambach, Axel, Pfeifer, Richard, Harper, Claudia, Mason, Chris, van Til, Niek P.
• Format: Article
• Language: English
• Subjects: glycosylation-independent lysosomal targeting; hematopoietic stem and progenitor cells; lentiviral vector; Original; Pompe disease; tag technology
• ISSN: 2329-0501; 2329-0501
• DOI: 10.1016/j.omtm.2022.10.017

Pompe disease is a rare genetic neuromuscular disorder caused by acid α-glucosidase (GAA) deficiency resulting in lysosomal glycogen accumulation and progressive myopathy. Enzyme replacement therapy, the current standard of care, penetrates poorly into the skeletal muscles and the peripheral and central nervous system (CNS), risks recombinant enzyme immunogenicity, and requires high doses and frequent infusions. Lentiviral vector-mediated hematopoietic stem and progenitor cell (HSPC) gene therapy was investigated in a Pompe mouse model using a clinically relevant promoter driving nine engineered GAA coding sequences incorporating distinct peptide tags and codon optimizations. Vectors solely including glycosylation-independent lysosomal targeting tags enhanced secretion and improved reduction of glycogen, myofiber, and CNS vacuolation in key tissues, although GAA enzyme activity and protein was consistently lower compared with native GAA. Genetically modified microglial cells in brains were detected at low levels but provided robust phenotypic correction. Furthermore, an amino acid substitution introduced in the tag reduced insulin receptor-mediated signaling with no evidence of an effect on blood glucose levels in Pompe mice. This study demonstrated the therapeutic potential of lentiviral HSPC gene therapy exploiting optimized GAA tagged coding sequences to reverse Pompe disease pathology in a preclinical mouse model, providing promising vector candidates for further investigation.